Abstracts Archive - Page 48 of 2607 - ACR Meeting Abstracts

Abstract Number: 0774 • ACR Convergence 2025
Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Jun Inamo¹, Aleksandra Bylinska², Miles Smith², Lauren Vanderlinden³, Christian Wright⁴, Tayte Stephens⁵, Marie Feser⁶, Christopher Striebich⁷, James O'Dell⁸, Jeffrey Sparks⁹, John Davis¹⁰, Jonathan Graf¹¹, Maureen McMahon¹², Elizabeth Solow¹³, Lindsy Forbess¹⁴, Athan Tiliakos¹⁵, David Fox¹⁶, Maria I. Danila¹⁷, Diane Lewis. Horowitz¹⁸, Jonathan Kay¹⁹, Judith James², V. Michael Holers²⁰, Kevin Deane²¹, Joel Guthridge² and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Colorado Anschutz Medical Campus, Monument, CO, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Oklahoma Health Science Center, Oklahoma City, OK, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁷University of Colorado, Aurora, CO, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Mayo Clinic, Rochester, MN, ¹¹UCSF, San Francisco, CA, ¹²UCLA David Geffen School of Medicine, Los Angeles, CA, ¹³UT Southwestern Medical Center, Dallas, TX, ¹⁴Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁵Emory University, Roswell, GA, ¹⁶University of Michigan, Dexter, MI, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Northwell Health, New Hyde Park, ¹⁹UMass Chan Medical School, Worcester, MA, ²⁰University of Colorado Anschutz Medical Campus, Aurora, ²¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²²The University of Colorado, Aurora, CO

Background/Purpose: Seropositive rheumatoid arthritis (RA) has an at-risk stage identifiable by elevations of antibodies to cyclic citrullinated peptide (CCP). Identifying the immunologic factors that distinguish…
Abstract Number: 0843 • ACR Convergence 2025
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
Dinesh Khanna¹, David Korman², Elana Bernstein³, Neil Kramer⁴, Vikas Majithia⁵, Philip J. Mease⁶, Georg Schett⁷, Jacques Azzi⁸, Richard Nash⁹, Ran Reshef³, Mohammad Cherry¹⁰, Ernesto Ayala⁵, Matthew Schwede¹¹, Monalisa Ghosh¹², Fabian Müller¹³, Alisha Desai¹⁴, San-San Ou¹⁵, Sharmila Das¹⁴, Jerill Thorpe¹⁶, Melissa Harnois¹⁴, Alexis Melton¹⁶, Ashley Koegel¹⁶ and Margrit Wiesendanger⁸, ¹University of Michigan, Ann Arbor, MI, ²Mountain Rheumatology, Denver, CO, ³Columbia University Irving Medical Center, New York, NY, ⁴Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Health One Cares, Denver, CO, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Swedish Cancer Institute, Seattle, WA, ¹²C. S. Mott Children's Hospital University of Michigan Health, Ann Arbor, MI, ¹³University Hospital of Erlangen, Erlangen, Germany, ¹⁴Bristol Myers Squibb, Princeton, NJ, ¹⁵Bristol Myers Squibb, Seattle, WA, ¹⁶Bristol Myers Squibb, Princeton
Background/Purpose: BMS-986353 (CC-97540) is an investigational CD19-directed T-cell therapy expressing the chimeric antigen receptor (CAR) used in globally-approved lisocabtagene maraleucel; it is manufactured via the…
Abstract Number: 0770 • ACR Convergence 2025
Interrelationships of Depression, Pain, and Gait Mechanics and their Associations with Physical Activity Levels Among People with Knee Osteoarthritis
Oiza Peters, Steven Garcia, Joy Itodo, Ogundoyin Ogundiran and kharma Foucher, UNIVERSITY OF ILLINOIS, CHICAGO, Chicago, IL
Background/Purpose: Depression is associated with low physical activity (PA) levels in people with knee osteoarthritis (KOA)1. Pain contributes to both depression and PA levels in…
Abstract Number: 0810 • ACR Convergence 2025
Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement
Alexandru Micu¹, Alexandru-Emil Matei², Yi-Nan Li³, Ann-Christin Pecher⁴, Tim Filla⁵, Jörg Henes⁶, Markus Eckstein⁷, Karin Klingel⁸, Jörg Distler⁹ and Andrea-Hermina Györfi¹⁰, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ³University Hospital of Düsseldorf, Düsseldorf, Germany, ⁴Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁶Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁷Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸Cardiopathology, Institute for Pathology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany, ⁹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁰Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc)-associated primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc, yet its underlying cellular and molecular pathomechanisms…
Abstract Number: 0438 • ACR Convergence 2025
Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis
Bindee Kuriya¹, Susan J. Bartlett², Marie-France Valois³, Janet Pope⁴, Carter Thorne⁵, Carol Hitchon⁶, Hugues Allard-Chamard⁷, Glen Hazlewood⁸, Gilles Boire⁹, Louis Bessette¹⁰ and Vivian Bykerk¹¹, ¹Mount Sinai Health, Toronto, Canada, ²McGill University, Beaconsfield, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Centre of Arthritis Excellence, Newmarket, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Retired, Sherbrooke, QC, Canada, ¹⁰Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiorenal-metabolic (CRM) therapies, such as SGLT-2 inhibitors and GLP-1 agonists, are medications that target interconnected pathways between cardiovascular, renal, and metabolic systems and may…
Abstract Number: 0760 • ACR Convergence 2025
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Sema Kaymaz-Tahra¹, Cansu Arslantürk Güneysu², Sinem Nihal Esatoglu³, Güllü Sandal Uzun⁴, Burak Ince⁵, Mete Kara⁶ and Gulen Hatemi³, ¹Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ²Sakarya Training and Research Hospital, Division of Rheumatology, Sakarya, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Hacettepe University, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Istanbul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, ⁶Izmir City Hospital, Division of Rheumatology, Izmir
Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).Methods: We performed a systematic…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 0020 • ACR Convergence 2025
Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
Anne Carlton, Lam Tsoi, Joseph Kirma, Jennifer Fox, Paul Harms and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Vasculitis encompasses multiple conditions united by end-organ damage due to an immune-mediated reaction against the vasculature. Leukocytoclastic vasculitis (LCV) is a subtype of cutaneous…
Abstract Number: 0833 • ACR Convergence 2025
Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA
Timothy Wilson¹, Claudia Lugo², Marie Feser³, Mark Gillespie⁴, Troy Torgerson⁵, Gary Firestein⁶, V. Michael Holers⁷, Kevin Deane⁸ and Kristen Demoruelle⁹, ¹Thomas Jefferson University, Philadelphia, PA, ²University of Colorado, Denver, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Allen Institute for Immunology, Enumclaw, WA, ⁶University of California, San Diego, San Diego, CA, ⁷University of Colorado Anschutz Medical Campus, Aurora, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: The presence of serum anti-CCP-IgG antibodies can predict the future development of clinically evident RA. Neutrophil extracellular trap (NET) formation can be a source…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 0824 • ACR Convergence 2025
Characterizing Immune Responses in Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
Lwiza AitDowd¹, Ekaterina Murzin², Alexandra Pommier³, Ki Pui Lam⁴, Claudia Harris⁵, Melanie Kohlheim⁶, Grant Schulert⁷, Marc Sudman⁸, Eveline Wu⁹, Laura Schanberg¹⁰, Peter Nigrovic¹¹, James Lederer¹² and Lauren Henderson¹³, ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Childrens Hospital, Boston, MA, ⁶CARRA, Granville, OH, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, ⁹UNC Chapel Hill, Chapel Hill, NC, ¹⁰Duke University Medical Center, DURHAM, NC, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Brigham and Women's Hospital, Millis, MA, ¹³Boston Children's Hospital, Watertown, MA
Background/Purpose: Our ability to tailor treatments to individual patients with JIA remains limited. To identify candidate biomarkers that may be associated with treatment response, we…
Abstract Number: 0837 • ACR Convergence 2025
Risk of New Proteinuria in Next Ten Years in SLE
Michelle Petri¹, Ilayda Demirayak², Andrea Fava³, Daniel Goldman¹ and Laurence Magder⁴, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Istanbul University, Istanbul, Turkey, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The current 2024 ACR Lupus Nephritis guidelines recommend checking the urine protein to creatinine ratio (UPCR) every 6-12 months. Early recognition of lupus nephritis…
Abstract Number: 0796 • ACR Convergence 2025
Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics
Manon LESTURGIE-TALAREK¹, Francesco Carbone², Virginie Gonzalez³, Adrien Schvartz², Sophie Hecquet⁴, Fiona Oudart⁵, Marion Thomas⁶, Roberto D'Alessandro⁷, Yannick Allanore⁸, Mickael Menager² and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²Institut Imagine, Paris, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵APHP - Cochin hospital, Paris, France, ⁶APHP, Paris, France, ⁷Cochin Hospital, Paris, ⁸Université Paris Cité, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is driven by complex inflammatory pathways involving immune cell infiltration into synovial tissue and fluid. Synovial fluid (SF) provides direct insight…
Abstract Number: 0822 • ACR Convergence 2025
Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis
Kavya Sugur¹, Elizabeth Sloan², Emily Chong³, Sophia Matossian³, Katarina Kmetova⁴, Alyssa Rosek⁵, Christine Goudsmit⁶, Celine C. Berthier⁶, Pei-Suen Tsou³, Yu (Ray) Zuo³ and Jessica Turnier⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³University of Michigan, Ann arbor, MI, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, ⁷University of Michigan, Saline, MI
Background/Purpose: Most children with juvenile dermatomyositis (JDM) have chronic disease despite multi-drug immunosuppression, highlighting the need for targeted therapies. Neutrophil extracellular traps (NETs) are key…
Abstract Number: 0744 • ACR Convergence 2025
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Delia Fernandez-Lozano¹, Marta Domínguez-Álvaro², Javier Narváez³, Noemí Garrido⁴, Eugenio de Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez Martín¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro Cáceres¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, rafeal Benito-Melero¹⁶, Maria Garcia-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ⁹Hospital Universitario Donostia, San Sebastian, Spain, ¹⁰Hospital León, LEON, Castilla y Leon, Spain, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Galdakao-Usansolo University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁶MD, barcelona, Spain, ¹⁷Hospital Ramón y Cajal, Madrid, Spain, ¹⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁹Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].